New insider activity at Blueprint Medicines ( (BPMC) ) has taken place on June 5, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Percy H. Carter, the Chief Scientific Officer of Blueprint Medicines, has recently sold 2,659 shares of the company’s stock. This transaction was valued at a substantial $340,032.
Recent Updates on BPMC stock
In the last 24 hours, Blueprint Medicines experienced significant developments following the announcement of its acquisition by Sanofi for $129 per share in cash, with additional contingent value rights. This acquisition news led to various analysts adjusting their price targets and ratings for Blueprint Medicines. UBS raised its price target due to the acquisition announcement, while Citi upgraded the stock to Neutral from Sell, citing the acquisition’s expected smooth regulatory process and lack of competitive bids. Conversely, Guggenheim downgraded the stock to Neutral from Buy, and Stephens downgraded it to Equal Weight from Overweight, reflecting the acquisition’s impact on the company’s independent growth prospects. Citizens JMP also downgraded Blueprint to Market Perform, emphasizing the fairness of Sanofi’s offer and the unlikelihood of competing bids. Overall, the acquisition has prompted a reevaluation of Blueprint’s future prospects, influencing analysts’ recommendations and price targets.
Spark’s Take on BPMC Stock
According to Spark, TipRanks’ AI Analyst, BPMC is a Neutral.
Blueprint Medicines’ overall score is primarily impacted by its strong financial growth potential and positive earnings call sentiment. However, profitability challenges and an overvalued stock, as indicated by the P/E ratio, weigh heavily on the score. Technical indicators show a bullish trend, but potential overbought conditions warrant caution. The corporate merger event, while positive, is excluded from weighted scoring but is a significant strategic advantage.
To see Spark’s full report on BPMC stock, click here.
More about Blueprint Medicines
YTD Price Performance: 46.90%
Average Trading Volume: 2,112,621
Technical Sentiment Signal: Buy
Current Market Cap: $8.24B
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue